Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Impact of Disease-Modifying Therapies on the Survival of Patients with Multiple Sclerosis in Taiwan, 1997-2008.
Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis.
Epigenetics of Multiple Sclerosis: An Updated Review.
Therapy Optimization in Multiple Sclerosis: A cohort study of therapy adherence and risk of relapse.
Checklist for reporting and reviewing studies of experimental animal models of multiple sclerosis and related disorders.
Neurovascular and Immuno-Imaging Symposium
Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: A brief overview.
Episode 9 with Dr. Amit Bar-Or on how pediatric MS can illuminate early mechanisms of the disease
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.
The force awakens: insights into the origin and formation of microglia.
FOCIS Advanced Course in Basic and Clinical Immunology
Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study.
American Academy of Neurology Annual Meeting
Episode 29 with Dr. Monica Carson on MS research funding
White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.
FOCIS 2013: Improving Human Health Through Immunology
Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada) in Multiple Sclerosis
Teriflunomide attenuates immunopathological changes in the dark agouti rat model of experimental autoimmune encephalomyelitis.
The endocannabinoid system and multiple sclerosis.
Understanding the Metabolic Consequences of Human Arylsulfatase A Deficiency through a Computational Systems Biology Study.
Child Neurology Society 41st Annual Meeting
The "poison chair" treatment for multiple sclerosis.
Rituximab does not reset defective early B cell tolerance checkpoints.
Intrathecal interferon reduces exacerbations of multiple sclerosis.
The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.

Pages